Zachary Bessette

GU Oncology Now

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) provides a better overall survival (OS) at 5 years and significantly improves disease-specific survival (DSS) compared with gemcitabine and cisplatin (GC) in the perioperative setting for patients with muscle-invasive bladder cancer (MIBC), according to a <a href="https://meetinglibrary.asco.org/embargo/record/219854/abstract" target="_blank" rel="noopener">late-breaking abstract</a> presented at the American Society of Clinical Oncology 2023 Annual Meeting.Previous results of the GETUG/AFU V05 VESPER phase 3 trial showed that dd-MVAC improved 3-year progression-free survival (PFS) compared with GC in the perioperative setting for patients with MIBC. In the neoadjuvant setting, better bladder control and significant difference in 3-year PFS were reported in the dd-MVAC group (P=.025).Christian Pfister, MD, PhD, and colleagues reported the final analysis of VESPER, including OS data after 5 years of follow-up from randomization. A total of 437 patients received neoadjuvant chemotherapy, 60% of whom received the planned 6 cycles in the dd-MVAC arm, 84% received 4 cycles in the GC arm, and 91% and 90% of patients underwent surgery, respectively.Results of the 5-year analysis showed that OS was improved in the dd-MVAC arm compared with the GC arm (64% vs 56%, respectively; hazard ratio [HR], 0.77; 95% CI, 0.58-1.03; P=.078), as was DSS (72% vs 59%, respectively; HR, 0.63; 95% CI, 0.46-0.86; P=.004).Similarly, OS was significantly improved in the dd-MVAC arm in the neoadjuvant group (66% vs 57%, respectively; HR, 0.71; 95% CI, 0.52-0.97; P=.032) as was DSS (75% vs 60%, respectively; HR, 0.56; 95% CI, 0.39-0.80; P=.001).Dr. Pfister and colleagues acknowledged that the main cause of death was bladder cancer progression (83%).These results led authors to conclude that &ldquo;dd-MVAC provides a better OS at 5 years and significantly improves DSS compared with GC in the perioperative setting of MIBC.&rdquo;

VESPER: 5-Year Overall Survival After Perioperative Chemotherapy Regimens for MIBC

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

dd-MVAC provides a better OS at 5 years and significantly improves DSS compared with GC in the perioperative setting for patients with MIBC.

VESPER: 5-Year OS After Perioperative Chemotherapy for MIBC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe